Anosmia: Symptoms, Causes & Treatment

Anosmia (complete olfactory loss) and hyposmia (partial olfactory reduction) are clinically underrecognized conditions with significant impact on quality of life — approximately 80% of taste perception is olfactory-dependent, so anosmia causes concomitant taste dysfunction (ageusia) perceived as food tasting bland or wrong. Safety risks include inability to detect smoke, gas leaks, and spoiled food. Depression and social isolation are common. Prevalence is estimated at 3–20% in the general population, higher with age.

COVID-19 dramatically elevated global awareness of anosmia — sudden-onset smell loss became one of the most specific early symptoms of SARS-CoV-2 infection. The mechanism involves infection of sustentacular (support) cells in the olfactory epithelium via ACE2 receptors, causing neuroinflammation and functional disruption without direct olfactory neuron infection in most cases — explaining the typically reversible nature (70–80% recover within 4 weeks). Persistent post-COVID anosmia or parosmia (distorted smells) affecting 5–10% of infected individuals represents a major public health burden from Long COVID.

The most common causes worldwide remain sinonasal disease (CRS with/without nasal polyps — most common), post-upper respiratory infection anosmia (post-viral — most common in younger patients), head trauma (shearing of olfactory nerve filaments at the cribriform plate), and medications. Anosmia as an early neurological marker is notable: it often precedes motor symptoms of Parkinson's disease and Alzheimer's disease by years — offering a potential early detection window.

• Complete (anosmia) or partial (hyposmia) inability to detect odors — may be sudden-onset (post-viral, trauma) or gradual (sinonasal, neurodegenerative)
• Concomitant ageusia (loss of flavor/taste) — because 80% of food flavor is olfactory-dependent; basic taste (sweet/sour/salty/bitter) is intact
• Parosmia: distortion of smell where familiar odors smell distorted or foul — common in post-COVID recovery, often more distressing than anosmia
• Phantosmia: phantom smells perceived without a stimulus (often burning, foul odors) — may indicate nasal or CNS pathology
• Safety risks: inability to detect smoke, gas leaks, rotten food
• Depression, reduced appetite, social withdrawal from inability to enjoy food and scents

• Chronic rhinosinusitis (CRS) with or without nasal polyps: the most common cause — inflammatory obstruction of olfactory cleft and mucosal edema blocking odorant access
• Post-infectious (post-viral): most common cause in young adults — influenza, rhinovirus, SARS-CoV-2; sustentacular cell damage or neuroinflammation
• Head trauma: shearing of olfactory nerve filaments at the cribriform plate during frontal or occipital impact — often complete and permanent
• COVID-19: ACE2-mediated sustentacular cell infection — usually reversible; persistent parosmia in 5–10%
• Medications: aminoglycosides, zinc nasal sprays (intranasal zinc linked to permanent anosmia), nasal topical cocaine, ACE inhibitors, methotrexate
• Neurodegenerative diseases: Parkinson's disease (hyposmia is one of the earliest prodromal features, preceding motor symptoms by 4–7 years); Alzheimer's dementia
• Nasal masses: inverted papilloma, sinonasal tumors; nasal/skull base surgery
• Idiopathic (10–20%)

Clinical history: onset (sudden vs. gradual), temporal relationship to infection, head trauma, medications, nasal symptoms. Nasal endoscopy: polyps, mucosal disease, olfactory cleft blockage. Psychophysical olfactory testing: Sniffin' Sticks (European standard) or UPSIT (University of Pennsylvania Smell Identification Test) — quantify hyposmia/anosmia severity. CT of sinuses: structural sinonasal disease, polyps, tumors. MRI: olfactory bulb volume (reduced in neurodegenerative disease); exclude anterior fossa mass. Neurological examination: assess for Parkinson's or cognitive impairment markers when neurodegenerative disease is suspected.

Treat underlying cause: intranasal and short-course systemic corticosteroids for CRS and nasal polyps (reduce edema, restore olfactory cleft patency); functional endoscopic sinus surgery (FESS) for refractory sinonasal disease or polyps. Olfactory training (smell training): repeated and structured exposure to 4 odors (rose, lemon, clove, eucalyptus) twice daily for ≥4 months — evidence-based for post-infectious (including post-COVID) and post-traumatic hyposmia; stimulates olfactory receptor neuron recovery and central plasticity. Omega-3 fatty acids: emerging evidence suggests benefit for post-COVID olfactory recovery. Alpha-lipoic acid: some evidence in post-viral anosmia. Platelet-rich plasma (PRP) intranasal application: under investigation for post-COVID parosmia. Post-traumatic anosmia: generally poor prognosis — spontaneous recovery in ~20% over 1–2 years; olfactory training worthwhile. Drug-induced anosmia: may partially recover after discontinuation of the offending agent.

• Malnutrition and weight loss: inability to enjoy food reduces appetite and dietary variety
• Safety hazards: smoke, gas leaks, spoiled food undetected — install smoke and gas detectors; use date labels on food
• Depression, anxiety, and significant quality-of-life impairment — often underestimated by clinicians
• Persistent parosmia (post-COVID): food aversions from distorted odors cause dietary restriction and social distress more severe than complete anosmia in many patients

• Prompt treatment of CRS and nasal polyps prevents progressive olfactory loss
• COVID-19 vaccination: reduces severity of infection and likelihood of prolonged post-COVID anosmia
• Avoid intranasal zinc products (sprays) — associated with permanent anosmia; oral zinc supplementation is safe
• Helmet use in contact sports and cycling to prevent head trauma